Skip to main content

Macrogenics Inc 8-K, filed Oct 23, 2026

Macrogenics Inc (MGNX)

8-K 2026-10-23 For: 2026-10-23
View Original
Added on October 28, 2026

About this 8-K

Macrogenics Inc filed this 8-K on October 23, 2026.

MacroGenics reported interim Phase 1 MGC026 data showing a 27% best overall response rate in heavily pretreated SCCHN patients, with no treatment-related discontinuations, and plans an early 2027 front-line pembrolizumab combination cohort. AI summary

Items reported

  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits